Molecular typing relies on molecular genetic screening and isn't but routinely readily available. Molecular subtypes and immunohistochemical surrogate markers of the tumors (HR, HER2, triple adverse) correlate in about 70%. The differentiation of luminal A and B subtypes by HR position and proliferation markers like Ki-67 could possibly be https://edwardu763szi1.wikitidings.com/user